Targeting Ubiquitin For Drug Discovery & Development
Summary
Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects for the future. With the FDA approval and commercialization of Velcade, scientists are now beginning to see the potential of this ever expanding science. New therapeutic targets are being explored and implicaWelcome!
Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects for the future. With the FDA approval and commercialization of Velcade, scientists are now beginning to see the potential of this ever expanding science. New therapeutic targets are being explored and implications for new compounds, line-extensions and combination therapies are on the horizon.
Scientific Advisory Board
Alejandro Bernal, Ph.D.
Senior Scientist
PROGENRA
Jianing Huang, Ph.D.
Associate Director, HTS
RIGEL PHARMACEUTICALS
Claudio Joazeiro, Ph.D.
Principal Investigator
THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF)
Frank Mercurio, Ph.D.
Director, Cell Signaling and Target Discovery
CELGENE
Michael Palladino
Senior Vice President, Chief Technology Officer, and Scientific Co-founder
NEREUS PHARMACEUTICALS
Yuval Reiss, D.Sc.
Chief Scientific Officer
PROTEOLOGICS
